Global Two years into his role, Ipsen’s EVP and Chief Medical Officer Prof. Dr. med. Steven Hildemann MD discusses his vision of patient-centricity and how he is leading a medical transformation that puts data-driven insights at the core and aims to make a real difference to both clinical practice and patients’…
UK Oxford Nanopore hogged the UK biotech headlines in 2021, raising GBP 195 million in a single venture capital round – the year’s largest – and scoring a GBP 350 million listing on the London Stock Exchange, according to new data from the UK BioIndustry Association (BIA) and Clarivate. See below…
Spain Soon after reaching its 60th anniversary, in 2015, the largest hospital in Catalonia and a group of sister institutions began working on the creation of a new type of campus. The idea was to follow the footsteps of world-leading healthcare hubs. The idea of strengthening the cluster was an…
Italy Luca Benatti, one of Italian biotech’s most notable entrepreneurs, outlines some of the key challenges of starting a biotech company in Europe, highlights how these barriers can be overcome, and gives some of the key lessons he has learned in his entrepreneurial journey. Benatti currently serves as CEO and…
Italy Serial bioentrepreneur Luca Benatti introduces EryDel, an Italian firm based on the concept of using a patient’s red blood cells to deliver drugs. Benatti also weighs in on the strengths and weaknesses of the Italian environment for biotech start-ups and his ambitious roadmap for EryDel’s future growth. The major…
Spain The Spanish Society of Biotechnology (SEBiot) is a non-profit organization established by academics and researchers to promote the sector through knowledge exchange and is a Branch Office of the European Federation of Biotechnology (EFB). Its current president, Fernando Peláez, explains the main activities of this scientific society, how SEBiot is…
Europe At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is being challenged and the policy measures that need to be enacted to solve this issue. Read on for five key…
Spain While Spain’s scientific infrastructure has long been hailed as world-class, the southern European nation has often struggled to translate its excellent science into viable commercial companies. However, a growing cadre of clinical-stage firms are aiming to change that narrative and become the biotech success story that Spain so desperately craves.…
Asia-Pacific To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC has identified six key trends for emerging biotechs to watch. For a full interview with Senthil Sockalingam, head of IQVIA…
Global Speaking from Ipsen’s US headquarters in Cambridge, Massachusetts off the back of a whirlwind first 16 months as the firm’s Chief Business Officer, Philippe-Lopes Fernandes outlines his deal-making philosophy, how the iconic French mid-cap represents a reliable partner for innovative biotechs looking to establish a global reach for their programs,…
Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…
Spain According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends include the fact that generics penetration in Spain has remained at a constant level for almost seven years and private…
See our Cookie Privacy Policy Here